Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Strategies to counteract side effects of new MS therapies

10.09.2009
Plasmapheresis for removal of natalizumab in patients with PML
Neurologist from the RUB present results in the New England Journal of Medicine

The drawback in the new immunotherapies in multiple sclerosis (MS) include severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

Prof. Ralf Gold (RUB Clinic for Neurology, St. Josef Hospital) and Dr. Werner Wenning (Ortenau Clinic, Offenburg-Gengebach) employed plasmapheresis to eliminate the active pharmaceutical agent and thus clear the virus from the brain. A report on their successful method of treatment has been published in the current edition of the New England Journal of Medicine.

Suppressing the destructive impact of leukocytes in MS

Natalizumab is a monoclonal antibody that has been approved for the treatment of severe RR MS (relapse remitting MS) in the EU since 2006. The antibody attaches to specific structures on the surface of white blood cells thus reducing their ability to attach to and pass through vascular wall into the inflamed tissue. The active agent thus suppresses the destructive effects of leukocytes that attack the myelin sheath, the insulating layer of nerve fibres. Leukocytes theoretically attack and destroy destructive foreign substances such as viruses or bacteria, thus the drawback of this medication is a decrease in the immune defense of the brain.

Unfulfilled hope: monotherapy is also not harmless

Clinical studies with Natalizumab led to progressive multifocal leukoencephalopathy (PML) in two MS patients. This severe brain infection is triggered by the JC virus found in about 80% of all adults. Normally the immune system does however control the virus. Less experienced physicians can easily mistake PML symptoms with an acute attack of MS. Prof. Gold explained that both study patients had also been administered the immune activating drug Interferon Beta, thus the hope that the monotherapy was relatively harmless had been realistic. Moreover, when the drug was approved at the beginning of summer 2006, the manufacturing company BiogenIdec had offered country-specific intensive preparatory seminars covering almost all precautionary and therapeutic measures. In July 2008, PML was diagnosed almost simultaneously in a German and Swedish MS patient, after 14 and 16 months of Natalizumab treatment respectively.

Treatment in Offenburg, supervision in Bochum

The strategies of treating the infection are the topic of the two studies that were simultaneously submitted for publication by the German and Swedish authors. The German patient was treated by Dr. Werner Wenning in Offenburg, and the therapy supervised by Prof. Gold in Bochum.

Plasmapheresis eliminates the active agent natalizumab

The treatment was targeted at re-establishing the patients own immune system to enable it to eliminate the JC virus. The physicians thus had to remove the active agent Natalizumab from the patient's body. Natalizumab circulates within the body for a very long time, taking an average half--life of 16 days (before the concentration is reduced by about 50%). The researchers in Bochum and Offenburg thus decided to perform Plasmapheresis. Subsequent measurements showed that the drug plasma level had dropped from 10,8 µg/ml to below 0,25 µg/ml within a week. In parallel a temporary improvement of the symptoms was observed. A secondary deterioration developed 4 weeks later, with increased motor deficits as well as clouding of consciousness. In this phase of the immune reconstruction inflammatory syndrome (IRIS), immune cells (cytotoxic lymphocytes) eliminate the virus in the brain. This leads to the destruction of the infected oligodendrocytes, supporting cells in the brain responsible for the insulation of the nerve cell connections. The patient required 4 weeks of intensive care, including artificial respiration and tube feeding, before he could be transferred for follow-up rehabilitation. The therapeutic measures have been described and discussed in detail in the manuscript.

Neurologist must know how to handle new side effects

Prof. Gold pointed out that new MS drugs unfortunately also have new side effects that can sometimes be fatal. Currently Natalizumab is the focal point of interest throughout the world, but that other new drugs, such as Alemtuzumab or anti-CD20 antibodies may soon follow. It is thus important that the neurologists are extremely well-informed about complications and the treatment thereof. In future, "therapeutic navigation" through modern immune therapies with escalation and de-escalation cycles according to the activity of the disease may be possible.

Title

Werner Wenning, Aiden Aghikia, Jörg Laubenberger, David B. Clifford, Peter F. Behrens, Andrew Chan, Ralf Gold: Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. In: N Engl J Med 361;11, 10.9.2009

Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29: 558-565

Further Information

Prof. Ralf Gold, Neurological Clinic at the Ruhr-University Bochum in St. Josef-Hospital, Gudrunstraße 56, 44791 Bochum, Tel.: 0234/509-2410, Fax: 0234/509-2414, E-Mail: ralf.gold@rub.de

Dr. Josef König | idw
Further information:
http://www.ruhr-uni-bochum.de/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>